Protara Therapeutics, Inc. (TARA)

AI-Powered SEC Filing Analysis

Insider Trading Filed: 2026-04-09

Key Insights

  • The reported transaction was a sale of 1,134 shares of common stock by Jacqueline Zummo, the Chief R&D Officer of Protara Therapeutics, Inc.
  • The sale was made pursuant to a Rule 10b5-1 trading plan established by the reporting person, indicating pre-planned insider selling activity.
  • Following the reported transaction, the reporting person still beneficially owns 94,827 shares of the company's common stock, maintaining a significant ownership stake.
Filing tone (AI): Neutral
View Original Filing →

Filings on this page are at least 90 days old. In the app, any new Protara Therapeutics, Inc. filing is analysed the moment you open it.

Download on theApp Store Get it onGoogle Play

Important Information

AI-generated analysis is for informational purposes only. Always read original SEC filings and consult with qualified professionals before making investment decisions.